LLY

796.56

-2.62%↓

JNJ

153.68

-0.88%↓

ABBV

187.46

-1.44%↓

NVO

74.85

-2.79%↓

UNH

308.12

+0.46%↑

LLY

796.56

-2.62%↓

JNJ

153.68

-0.88%↓

ABBV

187.46

-1.44%↓

NVO

74.85

-2.79%↓

UNH

308.12

+0.46%↑

LLY

796.56

-2.62%↓

JNJ

153.68

-0.88%↓

ABBV

187.46

-1.44%↓

NVO

74.85

-2.79%↓

UNH

308.12

+0.46%↑

LLY

796.56

-2.62%↓

JNJ

153.68

-0.88%↓

ABBV

187.46

-1.44%↓

NVO

74.85

-2.79%↓

UNH

308.12

+0.46%↑

LLY

796.56

-2.62%↓

JNJ

153.68

-0.88%↓

ABBV

187.46

-1.44%↓

NVO

74.85

-2.79%↓

UNH

308.12

+0.46%↑

Search

Allogene Therapeutics Inc

Open

SectorGezondheidszorg

1.35 -1.46

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1.34

Max

1.4

Belangrijke statistieken

By Trading Economics

Inkomsten

206K

-60M

EPS

-0.28

Winstmarge

272,450

Werknemers

226

EBITDA

-302K

-56M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+479.85% upside

Dividenden

By Dow Jones

Volgende Winsten

6 aug 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

53M

308M

Vorige openingsprijs

2.81

Vorige sluitingsprijs

1.35

Nieuwssentiment

By Acuity

50%

50%

164 / 381 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

Allogene Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

16 jun 2025, 22:33 UTC

Acquisities, Fusies, Overnames

KKR to Acquire Australian Power Provider Zenith Energy

16 jun 2025, 21:55 UTC

Belangrijke Marktbewegers

Geospace Technologies Shares Up on Petrobras Pact

16 jun 2025, 17:04 UTC

Belangrijke Marktbewegers

Roku Shares Climb on Advertising Deal with Amazon

16 jun 2025, 23:51 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

16 jun 2025, 23:51 UTC

Marktinformatie

Nikkei May Trade Range Bound Amid Israel-Iran Conflict -- Market Talk

16 jun 2025, 23:41 UTC

Marktinformatie

Gold Edges Higher Amid Ongoing Geopolitical Tensions -- Market Talk

16 jun 2025, 23:10 UTC

Marktinformatie
Acquisities, Fusies, Overnames

XRG Has 'Viable Path' to Approval of Santos Takeover -- Market Talk

16 jun 2025, 23:02 UTC

Marktinformatie

Auckland Airport Unlikely to Hit Target for International Passengers -- Market Talk

16 jun 2025, 22:32 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Santos Unlikely to Attract Rival Bidder to XRG -- Market Talk

16 jun 2025, 22:03 UTC

Acquisities, Fusies, Overnames

KKR & Co. to Buy Zenith Energy From Consortium Including Pacific Equity Partners, OPSEU Pension Trust, Foresight Group >KKR

16 jun 2025, 22:00 UTC

Acquisities, Fusies, Overnames

KKR Acquires Leading Australian Independent Power Producer Zenith Energy >KKR

16 jun 2025, 21:56 UTC

Winsten

Lennar Has an Earnings Miss. The Stock Slips. -- Barrons.com

16 jun 2025, 21:10 UTC

Acquisities, Fusies, Overnames

Mitsubishi in Talks to Sign $8 Billion Deal With Gas Producer Aethon -- WSJ

16 jun 2025, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

16 jun 2025, 20:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

16 jun 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

16 jun 2025, 20:49 UTC

Marktinformatie

Fitch Revises Canadian Provinces Fiscal Outlook to 'Deteriorating' -- Market Talk

16 jun 2025, 20:14 UTC

Acquisities, Fusies, Overnames

Update: EchoStar Stock Surges. It's Short Covering and President Trump. -- Barrons.com

16 jun 2025, 20:13 UTC

Marktinformatie

Natural Gas Gains on Warmer Outlook -- Market Talk

16 jun 2025, 19:58 UTC

Acquisities, Fusies, Overnames

OpenAI and Microsoft Tensions Are Reaching a Boiling Point -- WSJ

16 jun 2025, 19:13 UTC

Marktinformatie

Middle-East Conflict May Not Push Up Oil Long Term -- Market Talk

16 jun 2025, 19:09 UTC

Marktinformatie

Amazon-Roku Deal Shows Competition for Streaming Ad Space -- Market Talk

16 jun 2025, 18:43 UTC

Marktinformatie

May Could Mark Nascent Recovery in Canada Housing Market -- Market Talk

16 jun 2025, 18:36 UTC

Marktinformatie

Soybeans May Get Boost from Renewable Fuel Obligations -- Market Talk

16 jun 2025, 18:29 UTC

Marktinformatie

Global Equities Roundup: Market Talk

16 jun 2025, 18:29 UTC

Marktinformatie

Shopify Appears More Resilient Than Feared -- Market Talk

16 jun 2025, 18:22 UTC

Marktinformatie

Citi Forecasts Downturn in Gold Futures -- Market Talk

16 jun 2025, 16:42 UTC

Marktinformatie

Homebuyers' Downpayments Are Shrinking For First Time in 2 Years -- Market Talk

16 jun 2025, 16:37 UTC

Marktinformatie

Big, Beautiful Bill Might Not Mean Big Growth -- Market Talk

16 jun 2025, 16:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

Peer Vergelijking

Prijswijziging

Allogene Therapeutics Inc Prognose

Koersdoel

By TipRanks

479.85% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 7.77 USD  479.85%

Hoogste 14 USD

Laagste 2.5 USD

Gebaseerd op 14 Wall Street-analisten die 12-maands prijsdoelen bieden voor Allogene Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

14 ratings

11

Buy

3

Hold

0

Sell

Technische score

By Trading Central

1.18 / 1.69Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Weak Bullish Evidence

Lange Termijn

Weak Bearish Evidence

Sentiment

By Acuity

164 / 381 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Allogene Therapeutics Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.